These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9263524)

  • 1. [Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer].
    Koumura H; Sugiyama Y; Kunieda K; Saji S
    Gan To Kagaku Ryoho; 1997 Jul; 24 Suppl 2():324-31. PubMed ID: 9263524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases.
    Mimori K; Fukagawa T; Kosaka Y; Ishikawa K; Iwatsuki M; Yokobori T; Hirasaki S; Takatsuno Y; Sakashita H; Ishii H; Sasako M; Mori M
    Ann Surg Oncol; 2008 Oct; 15(10):2934-42. PubMed ID: 18661187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
    Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
    BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer.
    Ajisaka H; Yonemura Y; Miwa K
    Hepatogastroenterology; 2004; 51(57):900-5. PubMed ID: 15143943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of MMP-9 and TIMP-1 production during liver metastasis in colorectal cancer].
    Ogata Y; Ookita A; Kakegawa T
    Nihon Rinsho; 1995 Jul; 53(7):1811-5. PubMed ID: 7630024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
    Li L; Zhang S; Lin H; Lin JY
    Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
    Inuzuka K; Ogata Y; Nagase H; Shirouzu K
    J Surg Res; 2000 Oct; 93(2):211-8. PubMed ID: 11027463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer.
    Oshima T; Kunisaki C; Yoshihara K; Yamada R; Yamamoto N; Sato T; Makino H; Yamagishi S; Nagano Y; Fujii S; Shiozawa M; Akaike M; Wada N; Rino Y; Masuda M; Tanaka K; Imada T
    Oncol Rep; 2008 May; 19(5):1285-91. PubMed ID: 18425389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in peripheral blood of patients with gastric carcinoma].
    Yoshikawa T; Suzuki K; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y; Tsuburaya A
    Gan To Kagaku Ryoho; 1998 Jul; 25(9):1461-4. PubMed ID: 9703854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
    Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases.
    Zeng ZS; Cohen AM; Zhang ZF; Stetler-Stevenson W; Guillem JG
    Clin Cancer Res; 1995 Aug; 1(8):899-906. PubMed ID: 9816060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
    Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
    Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases.
    Illemann M; Bird N; Majeed A; Sehested M; Laerum OD; Lund LR; Danø K; Nielsen BS
    Mol Cancer Res; 2006 May; 4(5):293-302. PubMed ID: 16687484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation between the expression of urokinase-type plasminogen activator, E-cadherin and malignancy in gastric cancer].
    Itoh H; Yonemura Y; Tsuchihara K; Kawamura T; Nojima N; Kaji M; Fushida S; Nishimura G; Fujimura T; Miwa K
    Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():124-9. PubMed ID: 7611774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer.
    Kahlert C; Bandapalli OR; Schirmacher P; Weitz J; Brand K
    Anticancer Res; 2008; 28(3A):1459-65. PubMed ID: 18630499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases.
    Gentner B; Wein A; Croner RS; Zeittraeger I; Wirtz RM; Roedel F; Dimmler A; Dorlaque L; Hohenberger W; Hahn EG; Brueckl WM
    Anticancer Res; 2009 Jan; 29(1):67-74. PubMed ID: 19331134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma.
    Asano T; Tada M; Cheng S; Takemoto N; Kuramae T; Abe M; Takahashi O; Miyamoto M; Hamada J; Moriuchi T; Kondo S
    J Surg Res; 2008 May; 146(1):32-42. PubMed ID: 17543340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.